Botox as effective as medication for urinary urgency incontinence

Loyola research sheds light on treatments for common condition in women

2012-10-04

(Press-News.org) MAYWOOD – Botox® (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).

Urgency incontinence is urinary incontinence with a strong or sudden need to urinate. Traditionally, this condition has been treated with drugs known as anticholinergics, which reduce bladder contractions by targeting the bladder muscle through the nervous system. However, many women who take anticholinergic medications experience side effects, including constipation, dry mouth and dry eyes.

"Prior to this study, we reserved onabotulinum toxin-A for women who did not respond to traditional oral medication," said Linda Brubaker, MD, MS, co-author and dean, SSOM. "However, this research supports the use of either of these approaches as appropriate first-line treatment in women."

An estimated 15.7 percent of U.S. women experience urinary incontinence. Women are twice as likely to experience urinary incontinence as men.

This study evaluated 241 women with urinary urgency incontinence. One group of participants received six-months of daily oral medication plus a saline injection. The other group received one injection of onabotulinum toxin-A (Botox) plus a daily oral placebo capsule. At the beginning of the study, patients had an average of five urgency incontinence episodes a day. The average reduction in episodes over six months was 3.4 with oral medication and 3.3 with onabotulinum toxin-A. The proportion of women with complete resolution of urgency incontinence was 13 percent with anticholinergics and 27 percent with onabotulinum toxin-A. Quality of life improved in both groups without significant differences. More participants in the anticholinergic group reported dry mouth (46 percent versus 31 percent) while the onabotulinum toxin-A group had more urinary tract infections (28 percent versus 15 percent) and more incomplete bladder emptying, requiring temporary bladder catheterization (5 percent versus 0 percent).

"These results will help doctors weigh treatment options for women and make recommendations based on individual patient needs," said Dr. Brubaker, who is in the Division of Female Pelvic & Reconstructive Surgery, Loyola University Health System.

LUHS' Division of Female Pelvic Medicine and Reconstructive Surgery was the first of its kind in greater Chicago. It is still one of the few centers in the country that offers a single location for the multi-disciplinary diagnosis and treatment of women with pelvic floor disorders. LUHS' urogynecological surgeons, doctors with the combined expertise of gynecology and urology, provide the most advanced medical and surgical care available for women with problems related to the lower urinary tract and the pelvic floor.

### For more information, call 708-216-2180 or visit www.loyolamedicine.org.

ELSE PRESS RELEASES FROM THIS DATE:

Clot-busting enzymes are working 2 jobs

2012-10-04

The body's blood clot-busting enzymes are much busier than previously imagined, with new research showing that they also dispose of every cell that dies prematurely from disease or trauma. In research published today in Cell Reports, scientists from Monash University have demonstrated for the first time the enzyme t-PA, which plays a vital role in the removal of blood clots, is also a major player in the removal of necrotic, or dead, cells. Necrosis occurs when cells in living tissue die prematurely due to external stress or injury. The body's system for removing waste ...

The smell of Mom: Scientists find elusive trigger of first suckling in mice

2012-10-04

LA JOLLA, CA – A team led by biologists at The Scripps Research Institute has solved the long-standing scientific mystery of how mice first know to nurse or suckle. This basic mammalian instinct, which could be a key to understanding instinctive behavior more generally, was thought to be triggered by a specific odor (pheromone) that all mouse mothers emit. But, as described online ahead of print by the journal Current Biology on October 4, 2012, the trigger in mice turns out to be a more complicated blend of nature and nurture: a signature mix of odors, unique for each ...

In cancer, an embryonic gene-silencing mechanism gone awry

2012-10-04

There are some genes that are only activated in the very first days of an embryo's existence. Once they have accomplished their task, they are shut down forever, unlike most of our genes, which remain active throughout our lives. EPFL scientists have unveiled part of this strange mechanism. The same process, accidentally initiated later in life, could be responsible for many kinds of cancer. The discovery is described in a recent article in the journal Cell Reports. The researchers identified a group of proteins that play a key role in this phenomenon. They bind to a ...

BWH researchers discover genetic risk for uterine fibroids

2012-10-04

BOSTON, MA—Uterine fibroids are the most common type of pelvic tumors in women and are the leading cause of hysterectomy in the United States. Researchers from Brigham and Women's Hospital (BWH) are the first to discover a genetic risk allele (an alternative form of a gene) for uterine fibroids in white women using an unbiased, genome-wide approach. This discovery will pave the way for new screening strategies and treatments for uterine fibroids. The study will be published online on October 4, 2012 in The American Journal of Human Genetics. The research team, led by ...

Study shows benefits, drawbacks, for women's incontinence treatments

2012-10-04

Oral medication for treating a type of incontinence in women is roughly as effective as Botox injections to the bladder, reported researchers who conducted a National Institutes of Health clinical trials network study, with each form of treatment having benefits and limitations. After six months, women in both treatment groups said that the average number of daily episodes had declined from about five per day to about 1-2 per day. In the study, the researchers compared the effectiveness of Botox injections to oral anticholinergic medications for treating urge urinary ...

Babies learn the smell of mum

2012-10-04

Researchers show for the first time that a mammal begins to suckle its mother's milk through a learned response built on learning her unique combination of smells. When it is born, the newborn is exposed to the smell of its mother's amniotic fluid and the baby then responds to those smells to feed. Prevailing thought has been that pheromones –chemicals that trigger an innate behaviour – drove the suckling response as an automatic behaviour. The new work determines that, in mice, the smells must be learned before the behaviour can occur. Suckling is a critical step for ...

New function of a protein involved in colon cancer is identified

2012-10-04

Researchers from IMIM, Hospital del Mar Medical Research Institute, have succeeded in determining the function of a new variant of enzyme IKKalpha (IKKα) to activate some of the genes taking part in the tumor progressions of colorectal cancer. In the future, this fact will make it possible to design new drugs that inhibit this enzyme specifically and are less toxic for the remaining body cells, hence improving the treatment for this disease. The study is the culmination of previous research by the IMIM Research Group on Stem Cells and Cancer that had proven the ...

Penn researchers create a universal map of vision in the human brain

2012-10-04

PHILADELPHIA - Nearly 100 years after a British neurologist first mapped the blind spots caused by missile wounds to the brains of soldiers, Perelman School of Medicine researchers at the University of Pennsylvania have perfected his map using modern-day technology. Their results create a map of vision in the brain based upon an individual's brain structure, even for people who cannot see. Their result can, among other things, guide efforts to restore vision using a neural prosthesis that stimulates the surface of the brain. The study appears in the latest issue of Current ...

Better battlefield triage, transport may raise severely wounded soldiers' survival rates

2012-10-04

CHICAGO—Wounded soldiers who sustained chest injuries in Operation Enduring Freedom (Afghanistan) and Operation Iraqi Freedom (Iraq) had higher mortality rates than soldiers in Korea and Vietnam, according to a military trauma study presented at the 2012 American College of Surgeons Annual Clinical Congress. However, better battlefield triage and transport may have meant that severely wounded soldiers whom would have been considered killed in action in previous conflicts are more likely to get sent to trauma centers in the United States sooner in their course of care, ...

Chewing ability linked to reduced dementia risk

2012-10-04

Can you bite into an apple? If so, you are more likely to maintain mental abilities, according to new research from Karolinska Institutet in Sweden. The population is ageing, and the older we become the more likely it is that we risk deterioration of our cognitive functions, such as memory, decision-making and problem solving. Research indicates several possible contributors to these changes, with several studies demonstrating an association between not having teeth and loss of cognitive function and a higher risk of dementia. One reason for this could be that few ...

Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC

EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

Botox as effective as medication for urinary urgency incontinence

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: